Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 2
2004 4
2005 4
2006 3
2007 1
2008 4
2009 2
2010 2
2011 5
2012 5
2013 3
2014 2
2015 2
2016 4
2017 2
2018 3
2019 5
2020 10
2021 23
2022 21
2023 17
2024 17
2025 17
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.
Ligorio F, Provenzano L, Fotia G, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Mazzoli G, Jacobs F, Armani G, Sposetti C, Zurlo C, Menichetti A, Griguolo G, Faso V, Boldrini L, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L; PALMARES-2 study group; Vernieri C. Ligorio F, et al. Among authors: gennari a. Breast. 2026 Jun;87:104769. doi: 10.1016/j.breast.2026.104769. Epub 2026 Mar 31. Breast. 2026. PMID: 42048902 Free PMC article.
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.
De Angelis C, de Biase D, Gerratana L, Arpino G, Bianchini G, Castellano I, Curigliano G, Del Mastro L, Fabi A, Fusco N, Gennari A, Guarneri V, Zamagni C, Zambelli A, Malapelle U, Puglisi F. De Angelis C, et al. Among authors: gennari a. Breast. 2026 Jun;87:104786. doi: 10.1016/j.breast.2026.104786. Epub 2026 Apr 10. Breast. 2026. PMID: 41999684 Free PMC article. Review.
Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.
Nardin S, Vezzoli F, Cognolato G, Mollace R, Ramella Pollone B, Biello F, Cao D, Tagliamento M, Sarocchi M, Pagnesi M, Verdoia M, Conte B, Grisanti S, Genova C, Gennari A, Nardin M. Nardin S, et al. Among authors: gennari a. Front Pharmacol. 2026 Mar 19;17:1790897. doi: 10.3389/fphar.2026.1790897. eCollection 2026. Front Pharmacol. 2026. PMID: 41939827 Free PMC article. Review.
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database.
Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G; Eusoma Working Group. Aristei C, et al. Eur J Cancer. 2026 Mar 11;236:116259. doi: 10.1016/j.ejca.2026.116259. Epub 2026 Jan 30. Eur J Cancer. 2026. PMID: 41690148 Free article.
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2.
Mazzoli G, Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Fotia G, De Monte M, Ligorio F, Jacobs F, Armani G, Zurlo C, Menichetti A, Griguolo G, Faso V, Schianca AC, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L; PALMARES-2 study group; Vernieri C. Mazzoli G, et al. Among authors: gennari a. Breast. 2026 Apr;86:104692. doi: 10.1016/j.breast.2026.104692. Epub 2026 Jan 3. Breast. 2026. PMID: 41619649 Free PMC article.
Locally advanced breast cancers: the EUSOMA experience.
van Dam P, Tomatis M, Ponti A, Marotti L, Verhaegen J, Aristei C, Cardoso MJ, Cheung KL, Curigliano G, De Vries J, Santini D, Sardanelli F, Rubio IT; Eusoma Working group. van Dam P, et al. Eur J Surg Oncol. 2026 Mar;52(3):111303. doi: 10.1016/j.ejso.2025.111303. Epub 2025 Nov 25. Eur J Surg Oncol. 2026. PMID: 41391957 Free article.
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Cortés J, et al. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. N Engl J Med. 2025. PMID: 41124233 Clinical Trial.
152 results